HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mint Flavor Harvest For OTC Famotidine Pioneer Pepcid AC Follows Two ANDA Competitors

Executive Summary

Pepcid AC Maximum Strength (20 mg) in Icy Cool Mint tablets available in 20- and 40-count bottles. Walmart’s Equate and Sanofi’s Zantac 360 famotidine formulations already offer mint flavor options.

You may also be interested in...



Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine

Along with its Q1 results including a 7.3% drop in consumer health sales to 1.11bn ($1.35bn), Sanofi announces 10-mg famotidine tablets branded Zantac 360° will be available in the US in June.

US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations

FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.

Maximum Strength Pepcid AC Approval Calls For Postmarketing Study

Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel